Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID… (NCT04919031) | Clinical Trial Compass
CompletedNot Applicable
Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Persistent Symptoms
Egypt90 participantsStarted 2021-08-01
Plain-language summary
Inspiratory muscle training considered as safe and valid method to improve respiratory muscle strength and functional capacity among uncountable conditions which could improve post COVID-19 persistent symptoms including but not limited to respiratory muscle strength, diminishing dyspnea, enhance blood oxygenation, and patient's functional capacity and quality of life.
Who can participate
Age range40 Years – 60 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* sixty non hospitalized negative post covid-19
* men
* cigarette smokers
* 40-60 years old
* stage II Hypertensive (160-179 / 100-109 mmHg)
* Oxygen saturation less than 94%
* Severity of disease (Moderate Covid-19 affection)
* Body mass index (BMI) ranged from 25 to 29.9 kg/m2
* hemodynamically stable
* at least 4 weeks since first COVID-19 swab at time of screening
Exclusion Criteria:
* Patients with red flag indicators as chest pain, critical drop of oxygen saturation which require oxygen supply, severe level of hypoxia (blue lips)
* Unconscious patient
* Positive covid-19 patients
* Patients with cognitive impairment
* End-stage of chronic diseases
* BMI more than 30 kg/m2
* History of other cardiovascular disease as coronary artery disease, valvular heart disease, cardiac arrhythmias, congestive heart failure, myocardial infarction, stroke, transient ischemic attack, or peripheral vascular disease
* Neurological, neuromuscular, and musculoskeletal limitations
* Current active infection
* Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements.
* Participation in a clinical study or other type of research in the past 30 days